OticPharma is a private clinical-stage pharmaceutical company


OticPharma focuses on the acquisition and development of ear, nose, and throat (ENT) products that restore health and address unmet needs in children and adults.  The company’s proprietary foam program, (OP-01) is currently being developed for acute otitis externa (“swimmers ear”) and is also being explored for the treatment of nasal and sinus conditions.  The company’s proprietary surfactant program (OP-02) is currently being developed as a potential first-in-class, antibiotic-free treatment option for acute, recurrent, and chronic otitis media.

Read More

Recent Announcement


Tokai Pharmaceuticals and Otic Pharma Enter into Share Purchase Agreement

22-December-2016
BOSTON, Mass., IRVINE, Calif., and REHOVOT, Israel — (BUSINESS WIRE) — Dec. 22, 2016 — Tokai Pharmaceuticals Inc. (NASDAQ: TKAI) and Otic Pharma Ltd., a privately-held, clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose, and throat (ENT), today announced that the two companies, together with the shareholders of Otic Pharma, have entered into a definitive share purchase agreement under which the shareholders of Otic Pharma will become the majority owners of Tokai.

Explore OticPharma


icon6

COMPANY NEWS

Keep up on the latest public announcements, clinical activities, and company conference participations
icon1

R&D PROGRAMS

These programs are in development to prevent and treat disorders of the Ear, including Otitis Externa and Otitis Media.
icon5

LEADERSHIP TEAM

An experienced team of talented drug development and business pharmaceutical leaders
icon3

CONTACT US

Do you need more information or wish to contact one of our team members?